IRIDEX CORPORATION (NASDAQ:IRIX) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07.Submission of Matters to a Vote of Security Holders.
At the Annual Meeting of Stockholders of IRIDEX Corporation (“IRIDEX” or the “Company”) held on June13, 2018 (the “Annual Meeting”), the stockholders of IRIDEX elected the following individuals to the Board of Directors. Each Director will serve for the ensuing year or until their respective successors are duly elected and qualified.
|
Nominee |
Votes For |
Votes Against |
Abstentions |
Broker Non Votes* |
|
William M. Moore |
8,377,739 |
116,161 |
2,337,728 |
|
|
David I. Bruce |
8,383,688 |
110,212 |
2,337,728 |
|
|
Sanford Fitch |
8,377,439 |
116,461 |
2,337,728 |
|
|
Ruediger Naumann-Etienne, Ph.D. |
8,414,388 |
79,512 |
2,337,728 |
|
|
Ann D. Rhoads. |
8,206,015 |
287,885 |
2,337,728 |
|
|
Maria Sainz. |
8,414,588 |
79,312 |
2,337,728 |
* Broker non-votes do not affect the outcome of the election.
In addition, the following proposals were voted on and approved at the Annual Meeting.
|
Proposal |
Votes For |
Votes Against |
Abstentions |
Broker Non Votes |
|
Proposal to ratify the appointment of BPM LLP as the independent registered public accountants of the Company for the fiscal year ending December29, 2018 |
10,823,459 |
8,137 |
||
|
Proposal to approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as described in the proxy statement |
5,692,571 |
2,050,701 |
750,728 |
2,337,728 |
|
Proposal to approve the amended and restated 2008 Equity Incentive Plan |
7,174,848 |
573,424 |
745,728 |
2,337,728 |
About IRIDEX CORPORATION (NASDAQ:IRIX)
IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company’s ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.
